With a pivotal trial of its neuromodulation treatment for Alzheimer’s disease underway—and backed by a fresh influx of more than $70 million in VC funding—Cognito Therapeutics is now in the process of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, today announced executive leadership team appointments with Ralph Kern, M.D., as Chief Medical Officer and Kim Kwan as Chief Technology Officer ...
Cognito Therapeutics announced today that it entered into a collaboration with Ochsner Health to advance new approaches to ...
Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the ...
Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in ...
Discover the collaboration between Ochsner Health and Cognito Therapeutics to advance brain health innovations in New Orleans ...
Pharmaceutical Technology on MSN
Cognito Therapeutics and Ochsner partner for new brain health approaches
The Collaboratory leverages the expertise of Ochsner Health’s Neuroscience Institute.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication of a study in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results